Study finds similar glycocalyx biomarkers with isoflurane, sevoflurane: full analysis

Version 2

A new randomized, prospective canine study reports that isoflurane and sevoflurane produced similar serum endothelial glycocalyx biomarker profiles during anesthesia, with no significant between-group differences in syndecan-1 or hyaluronan. The study’s main signal was elsewhere: hyaluronan concentrations fell significantly after anesthesia, even though the inhalant agent itself did not appear to drive a difference. For clinicians, that makes this less a story about one gas being better than the other, and more a story about how difficult glycocalyx biology remains to interpret in everyday veterinary anesthesia.

That question has been building for several years. The endothelial glycocalyx, a carbohydrate-rich layer lining the vascular endothelium, has drawn increasing attention in both human and veterinary medicine because of its role in vascular permeability, coagulation, inflammation, and microcirculatory health. Reviews in veterinary medicine have highlighted syndecan-1 and hyaluronan among the best-known circulating markers of glycocalyx degradation, while also stressing that the field is still early and that biomarker behavior can be influenced by disease state, resuscitation, and sampling context. (sciencedirect.com)

Against that backdrop, the new study tested a focused peri-anesthetic question: whether the choice between two common inhalant anesthetics changes serum glycocalyx biomarker concentrations in dogs. According to the published abstract, it was a prospective randomized controlled trial comparing dogs anesthetized with sevoflurane versus isoflurane, using serum syndecan-1 and hyaluronan as endpoints. The investigators found no significant differences between anesthetic groups, despite a significant decrease in hyaluronan after anesthesia. (pmc.ncbi.nlm.nih.gov)

The result is notable partly because prior literature has left room for competing hypotheses. In human perioperative literature, volatile anesthetics, including sevoflurane, have sometimes been discussed as potentially glycocalyx-protective under specific conditions, but the evidence is not definitive and is shaped by surgical stress, inflammation, ischemia-reperfusion injury, transfusion, and fluid therapy. A 2019 review in BMC Anesthesiology concluded that some interventions, including sevoflurane, have been described as potentially protective, while also emphasizing that no specific glycocalyx-protective treatment is established for routine practice. (bmcanesthesiol.biomedcentral.com)

Veterinary evidence remains even thinner, which makes negative studies important. Related canine work has examined urinary syndecan-1 in dogs anesthetized with isoflurane or sevoflurane and found that investigators are still trying to sort out how anesthesia, IV crystalloids, and procedure duration affect measurable glycocalyx-associated markers. Other recent canine studies have looked at glycocalyx changes in settings such as cardiopulmonary bypass, trauma, and septic peritonitis, underscoring that illness severity and procedural intensity may be more informative models of glycocalyx disruption than routine inhalant selection alone. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the study supports a conservative interpretation: there’s currently no evidence here that choosing sevoflurane over isoflurane, or vice versa, meaningfully changes serum syndecan-1 or hyaluronan in this setting. That doesn’t make the finding unimportant. It helps narrow the question and suggests that if clinicians or researchers want to understand peri-anesthetic glycocalyx injury, they may need to look harder at confounders such as fluid strategy, hypotension, procedure length, underlying disease, and surgical invasiveness. It also reinforces that biomarker movement, like the observed decline in hyaluronan, may not map neatly onto a simple “more injury” or “less injury” framework. (frontiersin.org)

From an industry and research perspective, this is the kind of incremental study that can shape future protocol design. It doesn’t change anesthetic practice on its own, but it does add to the evidence base around what glycocalyx biomarkers can, and cannot, tell us in dogs. As glycocalyx-focused research expands in veterinary emergency and critical care, studies that define normal peri-anesthetic variation may become just as important as studies in sepsis or trauma, because they help establish the baseline against which illness-related changes are judged. (sciencedirect.com)

What to watch: The next step is likely more granular work, including larger cohorts, repeated time-point sampling, and analyses stratified by fluids, blood pressure support, and disease state, to determine whether clinically meaningful glycocalyx effects emerge under more stressful or prolonged anesthetic conditions. (pmc.ncbi.nlm.nih.gov)